LabKate said:

The phase 2 numbers were about 24% mean weight loss at 48 weeks on the top dose, with the curve still descending at the end of the study.

Careful with treating an unchanged LDL-C as a failure. If ApoB and triglycerides both fell, the particle picture improved regardless of what the calculated LDL says.

That is the short version; the long version is somebody else's post.

One concrete data point for the thread. For anyone tracking the class: GLP-1 alone gets you appetite, GLP-1 plus GIP adds tolerability and lipid handling, and adding glucagon adds expenditure and liver-fat reduction. Each addition also adds a receptor system that can generate side effects.

FDA_TrackerJim said:

Careful with treating an unchanged LDL-C as a failure.

Tracking labs for the lipid panel — here's the panel I get every 3 months and why:

• CMP: glucose, electrolytes, kidney function, liver enzymes
• Lipid panel: total cholesterol, LDL, HDL, triglycerides
• A1C: 3-month glucose average
• hsCRP: inflammatory marker
• CBC: blood counts, anemia screening
• B12, folate, iron: nutritional deficiency screening
• TSH, free T4: thyroid monitoring
• Lipase: pancreatic safety check

Total cost with insurance: about $40 copay. Without insurance, request cash-pay pricing from Quest/Labcorp — usually $195.

One thing that is still open after BenResearch_OR’s answer:

What the phase 2 dropout pattern implies about how the phase 3 tolerability will read?

Closing the loop on my own question.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.